GILD
Gilead Sciences, Inc.
Revenue by product
2025, ended Dec 31, 2025
Earlier:
Products by fiscal year
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty, contract and other revenues | 527M | 144M | 182M | 299M | 297M | 334M | 330M | 450M | 445M | 437M | — | — |
| Oncology | 3.24B | — | 2.93B | — | — | — | — | — | — | — | — | — |
Cell Therapy | 1.84B | — | 1.87B | — | — | — | — | — | — | — | — | — |
| 28.1B | 27.7B | 26.1B | 26.0B | 26.2B | 23.6B | 21.5B | 21.0B | 24.1B | 25.4B | 31.8B | 24.1B | |
| HIV | — | 19.6B | 18.2B | — | — | — | — | — | — | — | — | — |
| Liver Disease | — | 3.02B | — | 2.80B | — | — | — | — | — | — | — | — |
| Product sales | — | — | — | — | 27.0B | — | — | — | — | — | — | — |
Biktarvy | 14.3B | 13.4B | 11.9B | 10.4B | 8.6B | 7.3B | 4.7B | 1.2B | — | — | — | — |
Descovy | 2.76B | 2.11B | 1.99B | 1.87B | 1.70B | 1.86B | 1.50B | 1.58B | 1.22B | 0.30B | — | — |
Trodelvy | 1.40B | 1.32B | 1.06B | 0.68B | 0.38B | 49M | — | — | — | — | — | — |
Genvoya | 1.50B | 1.76B | 2.06B | 2.40B | 2.88B | 3.34B | 3.93B | 4.62B | 3.67B | 1.48B | 45M | — |
Vemlidy | 1.07B | 0.96B | 0.86B | 0.84B | 0.81B | 0.66B | 0.49B | 0.32B | 0.12B | 3.0M | — | — |
Yescarta | 1.50B | 1.57B | 1.50B | 1.16B | 0.70B | 0.56B | 0.46B | 0.26B | 7.0M | — | — | — |
Odefsey | 1.17B | 1.29B | 1.35B | 1.47B | 1.57B | 1.67B | 1.66B | 1.60B | 1.11B | 0.33B | — | — |
Sofosbuvir/Velpatasvir | 1.27B | 1.60B | 1.54B | 1.53B | 1.46B | 1.60B | 1.97B | 1.97B | 3.51B | — | — | — |
Other (Product sales) | 799M | 889M | 859M | 946M | — | — | — | — | — | — | — | — |
Symtuza - Revenue share | 495M | 592M | 529M | 530M | — | — | — | — | — | — | — | — |
Other Liver Disease | 874M | 467M | 385M | 426M | — | — | — | — | — | — | — | — |
Veklury | 0.91B | 1.80B | 2.18B | 3.91B | 5.57B | 2.81B | — | — | — | — | — | — |
Other HIV | 500M | 434M | 401M | 530M | 195M | 407M | 47M | 61M | 58M | 47M | — | — |
Tecartus | 344M | 403M | 370M | 299M | 176M | 44M | — | — | — | — | — | — |
Revenue share - Symtuza | — | — | — | — | 531M | 488M | 379M | 79M | — | — | — | — |
Other HCV | — | — | — | — | 207M | 193M | 328M | 498M | — | — | — | — |
Letairis | — | — | — | — | 206M | 314M | 618M | 943M | 887M | 819M | 700M | 595M |
Complera/Eviplera | — | — | — | — | 0.26B | 0.27B | 0.41B | 0.65B | 0.97B | 1.46B | — | — |
Stribild | — | — | — | — | 0.19B | 0.20B | 0.37B | 0.64B | 1.05B | 1.91B | 1.83B | 1.20B |
Truvada | — | — | — | — | 0.37B | 1.45B | 2.81B | 3.00B | 3.13B | 3.57B | 3.46B | 3.34B |
Ledipasvir/Sofosbuvir | — | — | — | — | 0.21B | 0.27B | 0.64B | 1.22B | 4.37B | — | — | — |
Viread | — | — | — | — | 0.11B | 0.19B | 0.24B | — | — | — | 1.11B | 1.06B |
Other HB/HDV | — | — | — | — | 44M | 18M | 11M | — | — | — | — | — |
Atripla | — | — | — | — | — | — | 0.60B | 1.21B | 1.81B | 2.61B | 3.13B | 3.47B |
Zydelig | — | — | — | — | — | — | 103M | 133M | 149M | 168M | 132M | 23M |
Ranexa | — | — | — | — | — | — | 216M | 758M | 717M | 677M | 588M | 510M |
Other Products, Viread | — | — | — | — | — | — | — | 0.31B | 1.05B | 1.19B | — | — |
Vosevi | — | — | — | — | — | — | — | — | 293M | — | — | — |
| Epclusa | — | — | — | — | — | — | — | — | — | 1.75B | — | — |
| Other Products | — | — | — | — | — | — | — | — | — | — | 174M | 167M |
| Antiviral Products | — | — | — | — | — | — | — | — | — | — | — | 22.8B |
Harvoni | — | — | — | — | — | — | — | — | — | 9.1B | 13.9B | 2.1B |
Complera Eviplera | — | — | — | — | — | — | — | — | — | — | 1.43B | 1.23B |
Sovaldi | — | — | — | — | — | — | — | — | — | — | 5.3B | 10.3B |
Other antiviral products | — | — | — | — | — | — | — | — | — | — | 69M | 88M |
| Total | 29.4B | 28.8B | 27.1B | 27.3B | 27.3B | 24.7B | 22.4B | 22.1B | 26.1B | 30.4B | 32.2B | 24.5B |